Aclaris Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Aclaris Therapeutics

02/05/2025 12:27

Aclaris Therapeutics Inc ACRS.OQ ACRS.O is expected to show a fall in quarterly revenue when it reports  results on May 5 (estimated) for the period ending March 31 2025

The Wayne Pennsylvania-based  company is expected to report a 46.6% decrease in revenue to $1.28 million from $2.4 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Aclaris Therapeutics Inc is for a loss of 12 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $7.00​, above​ its last closing price of $1.38. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.20
-0.22
-1.01
Missed
-362.1
Sep. 30 2024
0.04
-0.01
-0.11
Missed
-1,826.4
Jun. 30 2024
-0.20
-0.20
-0.15
Beat
26.6​
Mar. 31 2024
-0.26
-0.29
-0.24
Beat
16
​​Dec. 31 2023
-0.33
-0.34
-0.02
Beat
94.2
Sep. 30 2023
-0.47
-0.48
-0.41
Beat
14.6​
Jun. 30 2023
-0.44
-0.45
-0.42
Beat
6.7
Mar. 31 2023
-0.43
-0.44
-0.40
Beat
8.6

This summary was machine generated May 2 at 11:27 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)